AI Summary
Jim Cramer advises holding PFE for dividends amid low prices. PFE's stock fell over 7% in the past year. Cramer anticipates positive news related to Seagen acquisition. Overall market sentiment towards Vertex Pharmaceuticals' drug is negative. Cramer suggests patience for future growth opportunities.
Sentiment Rationale
While Cramer's advice supports holding PFE, the overall market has been cautious due to past performance.
Trading Thesis
Immediate market reactions may affect PFE but potential growth hinges on future news.
Market-Moving
- Jim Cramer advises holding PFE for dividends amid low prices.
- PFE's stock fell over 7% in the past year.
- Cramer anticipates positive news related to Seagen acquisition.
Key Facts
- Jim Cramer advises holding PFE for dividends amid low prices.
- PFE's stock fell over 7% in the past year.
- Cramer anticipates positive news related to Seagen acquisition.
- Overall market sentiment towards Vertex Pharmaceuticals' drug is negative.
- Cramer suggests patience for future growth opportunities.
Companies Mentioned
- PFE (PFE)
- VRTX (VRTX)
- NVDA (NVDA)
- QS (QS)
Market Recap
The article discusses PFE directly and provides insights about its current market stance.